Zilurgisertib
As of the edition of 20 October 2026, Zilurgisertib is a small molecule: in active development; acts on ACVR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Blood and lymph; Bones, joints and muscles; Cancer; Heart and blood vessels; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACVR1 | Activin receptor type-1 | Q04771 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 0 | 2 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Incyte | Lead sponsor of trials | 2021 to now |